Sphingosine Kinase 1-mediated Inhibition of Fas Death Signaling in Rheumatoid Arthritis B Lymphoblastoid Cells
Overview
Affiliations
Objective: It is becoming increasingly apparent that B cells play an important role in the pathogenesis of rheumatoid arthritis (RA). Due to the scarcity of B cells in RA, it has been technically difficult to functionally characterize B cell apoptosis in this disease. As a necessary first step to identify candidate aberrations, we investigated Fas-mediated signaling events in immortalized peripheral blood B lymphoblastoid cell lines (LCLs) from patients with RA and controls.
Methods: Cell death was determined by the MTS assay, and apoptosis was detected by the TUNEL assay and DNA laddering. Proteolytic activation of caspase 3 was determined by immunoblotting, and its enzymatic activity was determined by a fluorometric technique. Messenger RNA (mRNA) expression was quantified by real-time polymerase chain reaction (PCR) analysis. The functional role of sphingosine kinase (SPHK) was determined by measuring its enzymatic activity, by quantifying the levels of its product, sphingosine 1-phosphate (S1P), and by investigating the ability of the SPHK inhibitor N,N-dimethylsphingosine and isozyme-specific small interfering RNA (siRNA) oligonucleotides to reverse signaling aberrations.
Results: LCLs from patients with RA displayed disease-specific Fas-mediated signal transduction impairment with consequent resistance to cell death. RA LCLs displayed high constitutive SPHK activity and increased levels of S1P. Real-time PCR analysis showed higher SPHK-1 mRNA expression levels in RA patients compared with paired controls. Increased SPHK-1 (but not SPHK-2) mRNA levels were observed in synovial tissue from RA patients. Competitive inhibitors of SPHK reversed the resistance of RA LCLs to Fas-induced apoptosis. Additionally, resistance to Fas-mediated signaling was reversed by siRNA oligonucleotides specific for SPHK-1 but not by oligonucleotides specific for SPHK-2.
Conclusion: These findings demonstrate disease-specific resistance to Fas-mediated death signaling in patients with RA and implicate increased SPHK-1 activity as the cause of this aberration.
Lee J, Lee J, Im D Int J Mol Sci. 2025; 25(24.
PMID: 39769163 PMC: 11677552. DOI: 10.3390/ijms252413393.
Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases.
Burg N, Salmon J, Hla T Nat Rev Rheumatol. 2022; 18(6):335-351.
PMID: 35508810 PMC: 9641499. DOI: 10.1038/s41584-022-00784-6.
Zhu C, Wen S, Li J, Meng H, Zhang J, Zhao K Drug Des Devel Ther. 2021; 15:1981-1992.
PMID: 34007158 PMC: 8123953. DOI: 10.2147/DDDT.S293876.
Inoue T, Kohno M, Nagahara H, Murakami K, Sagawa T, Kasahara A PLoS One. 2019; 14(6):e0218090.
PMID: 31173610 PMC: 6555509. DOI: 10.1371/journal.pone.0218090.
Hutami I, Tanaka E, Izawa T Jpn Dent Sci Rev. 2019; 55(1):12-19.
PMID: 30733840 PMC: 6354287. DOI: 10.1016/j.jdsr.2018.09.004.